Microbot Medical Inc. announced on December 30, 2024, that it concluded the year by achieving several key milestones, positioning the company for continued success in 2025. A primary achievement was the recent FDA 510(k) submission for commercial approval of its LIBERTY Endovascular Robotic System.
The company's Chairman and CEO, Harel Gadot, stated that Microbot Medical had three main goals for 2024: completing the FDA 510(k) submission, establishing pre-commercial infrastructures, and executing strategic initiatives for future growth. These goals were met through the efforts of the team and collaboration with stakeholders.
Based on these achievements, Microbot Medical believes it has laid the necessary groundwork to support its commercial objectives in 2025. The company anticipates the launch of LIBERTY in Q2 2025 in the U.S. and plans to continue pursuing additional regulatory approvals outside the U.S.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.